Noah Rosenberg takes chief medical officer role at Esperion

Will develop and manage the firm’s clinical programmes

Noah Rosenberg has taken over as chief medical officer (CMO) at Esperion Therapeutics and will lead the Esperion clinical advisory board and develop and manage the company's clinical programmes. He will also manage the regulatory review process for the company's investigational therapies to treat cardiovascular and metabolic diseases.

Over the past decade, Dr Rosenberg has held senior posts in the pharmaceutical industry, including leadership roles in medical affairs, clinical development and administration in the US and globally at Pfizer, Sanofi and Forest Labs. He has experience working on compounds in all phases of drug development including late stage drugs such as Lipitor and Lantus. Most recently at Forest Research Institute, he led the in-licensing of the GK1-399 programme.

‘Esperion has an established reputation for productivity and success and I look forward to moving novel therapies such as ETC-1002 further along in clinical development,’ Dr Rosenberg said.

You may also like

Manufacturing

Touchlight partners with SVF Vaccines to advance dual hepatitis B/D vaccine into clinical development

The pair will progress an innovative dual-targeting hepatitis B and D vaccine into clinical trials, leveraging Touchlight's enzymatic doggybone DNA platform, which has demonstrated significant dose-sparing potential compared to traditional plasmid DNA
Pharmaceutical

From complexity to confidence: Smurfit Westrock finds a better way to ensure accuracy with EyeC

Demands for printing perfection and regulatory compliance, Smurfit Westrock faced growing complications in producing multilingual pharmaceutical inserts
Research & Development

Oxford BioTherapeutics signs T-cell engager collaboration with Bristol Myers Squibb for solid tumour targets

The company has entered a multi-year collaboration with BMS to discover and develop next-generation T-cell engager therapies for solid tumours using its OGAP-Verify platform, marking the company's third major pharma partnership in twelve months following deals with GSK and Roche
Research & Development

Applied Biopharm Consulting awarded Innovation funding to validate AI-powered AAV vector engineering platform

Irish biotech consultancy Applied Biopharm Consulting has secured an Innovation Voucher from the Local Enterprise Office Cork North & West to collaborate with an academic partner in validating its computational platform for adeno-associated virus vector optimisation through laboratory testing
Manufacturing

L.B. Bohle hosts successful continuous manufacturing workshop in Brazil

Focus on continuous wet granulation and drying for research, development and small-scale production
Manufacturing

Swiss Rockets collaborates with Lonza to advance Torqur’s oncology drug candidate bimiralisib into late-stage clinical development

Lonza to provide cGMP manufacturing and technical support to advance bimiralisib into late-stage clinical development
Research & Development

Phesi analysis finds 6.7% of global clinical trials affected by Middle East disruption

A Phesi analysis of more than 65,000 active clinical trials has found that 4361 studies are impacted by Middle East disruption, with Phase III oncology trials most exposed and all top ten global pharma companies holding significant investigator site presence in affected countries
Subscribe now